Home / Business and Economy / India's Pharma Giants: API Powerhouse or Custom Synthesis Stars?
India's Pharma Giants: API Powerhouse or Custom Synthesis Stars?
17 Oct
Summary
- India's API market to reach $22.18 billion by 2031.
- China supplies 73.71% of India's API imports.
- Three Indian firms show different business models for growth.
India's pharmaceutical sector is experiencing robust growth, with its Active Pharmaceutical Ingredient (API) market anticipated to reach $22.18 billion by 2031. Despite this expansion, the nation faces import dependence, with China supplying 73.71% of its API, bulk drug, and drug intermediate needs in FY25.
Three prominent Indian pharmaceutical companies—Aurobindo Pharma, Laurus Labs, and Divi's Laboratories—are navigating this landscape with distinct business models. Aurobindo Pharma focuses on integrated API manufacturing and contract development services. Laurus Labs leverages its API portfolio and expanding contract development and manufacturing organization (CDMO) business.
Divi's Laboratories excels in generic APIs, intermediates, and custom synthesis for global pharmaceutical innovators. By Q1FY27, Divi's custom synthesis contributed approximately 60% of its standalone revenue, highlighting a shift towards higher-value services.
These companies are investing heavily in capacity and technology. Divi's, for instance, reported over ₹1,500 crore in capital expenditure in FY26. Ensuring consistent quality and environmental compliance are critical for success in this competitive global market.
